2011AHPBA美國(guó)肝細(xì)胞癌療前評(píng)估
《2011AHPBA美國(guó)肝細(xì)胞癌療前評(píng)估》內(nèi)容簡(jiǎn)介：
Staging of hepatocellular carcinoma （HCC） is complex and relies on multiple factors including tumorextent and hepatic function. No single staging system is applicable to all patients with HCC. The stagingof the American Joint Committee on Cancer / International Union for Cancer Control should be used topredict outcome following resection or liver transplantation.
《2011AHPBA美國(guó)肝細(xì)胞癌療前評(píng)估》內(nèi)容預(yù)覽：
The Barcelona Clinic Liver Cancer scheme isappropriate in patients with advanced HCC not candidate for surgery. Dual phase computed tomographyor magnetic resonance imaging can be used for pretreatment assessment of tumor extent but theaccuracy of these methods remains poor to characterize <1 cm lesions. Assessment of tumor responseshould not rely only on tumor size and new imaging methods are available to evaluate response to therapyin HCC patients. Liver volumetry is part of the preoperative assessment of patients with HCC candidatefor resection as it reflects liver function. Preoperative portal vein embolization is indicated in patients withsmall future liver remnant （ 20% in normal liver; 40% in fibrotic or cirrhotic liver）。 Tumor size is not acontraindication to liver resection. Liver resection can be proposed in selected patients with multifocalHCC. Besides tumor extent, surgical resection of HCC may be performed in selected patients withchronic liver disease.
點(diǎn)擊下載***：《2011AHPBA美國(guó)肝細(xì)胞癌療前評(píng)估》
本站所注明來(lái)源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來(lái)源和作者，不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們
聯(lián)系z(mì)lzs@120.net，我們將立即進(jìn)行刪除處理
熱點(diǎn)圖文
-
2013我國(guó)胰腺囊性腫瘤共識(shí)意見草案
本共識(shí)意見（草案）依據(jù)我國(guó)胰腺囊性腫瘤的最近研究，并參考國(guó)際相關(guān)指南和研究...[詳細(xì)]
-
2013NCCN結(jié)直腸癌指南
在美國(guó)，結(jié)直腸癌發(fā)病率占所有癌癥的第四位，而死亡率為第二位。2012年估計(jì)...[詳細(xì)]
